Growth and growth hormone treatment in Turner syndrome

International Congress Series

Volumn 1298, Issue , 2006, Pages 33-41

  Davenport, Marsha L ^a   de Muinck Keizer Schrama, Sabine M P F ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Drug therapy; Growth; Human growth hormone; Short stature; Turner syndrome

Indexed keywords

EID: 33748929724     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2006.06.014     Document Type: Article

References (59)

1. Lyon A.J., Preece M.A., and Grant D.B. Growth curve for girls with Turner syndrome. Arch. Dis. Child. 60 10 (1985) 932-935
2. Ranke M.B., et al. Spontaneous growth in Turner's syndrome. Acta Paediatr. Scand., Suppl. 343 (1988) 22-30
3. Karlberg J., et al. Growth in infancy and childhood in girls with Turner's syndrome. Acta Paediatr. Scand. 80 12 (1991) 1158-1165
4. Davenport M.L., et al. Growth failure in early life: an important manifestation of turner syndrome. Horm. Res. 57 5-6 (2002) 157-164
5. Even L., et al. Longitudinal analysis of growth over the first 3 years of life in Turner's syndrome. J. Pediatr. 137 4 (2000 (Oct.)) 460-464
6. Rongen-Westerlaken C., et al. Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment. Acta Paediatr. 86 9 (1997 (Sep.)) 937-942
7. Rappold G.A., et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J. Clin. Endocrinol. Metab. 87 3 (2002 (Mar.)) 1402-1406
8. Ellison J.W., et al. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum. Mol. Genet. 6 8 (1997 (Aug.)) 1341-1347
9. Munns C.J., et al. Expression of SHOX in human fetal and childhood growth plate. J. Clin. Endocrinol. Metab. 89 8 (2004 (Aug.)) 4130-4135
10. Gravholt C.H., and Naeraa R.W. Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am. J. Med. Genet. 72 4 (1997 (Nov. 12)) 403-408
11. Clement-Jones M., et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum. Mol. Genet. 9 5 (2000 (Mar. 22)) 695-702
12. Blaschke R.J., and Rappold G.A. SHOX: growth, Leri-Weill and Turner syndromes. Trends Endocrinol. Metab. 11 6 (2000 (Aug.)) 227-230
13. Elder D.A., et al. Kyphosis in a turner syndrome population. Pediatrics 109 6 (2002 (Jun.)) e93
14. Kim J.Y., Rosenfeld S.R., and Keyak J.H. Increased prevalence of scoliosis in Turner syndrome. J. Pediatr. Orthop. 21 6 (2001 (Nov.)) 765-766
15. Allen D.B. Safety of human growth hormone therapy: current topics. J. Pediatr. 128 5 Pt 2 (1996) S8-S13
16. Rosenfeld R.G., et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J. Pediatr. 132 2 (1998 (Feb.)) 319-324
17. Van Pareren Y.K., et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J. Clin. Endocrinol. Metab. 88 3 (2003 (Mar.)) 1119-1125
18. Pasquino A.M., et al. Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group. J. Endocrinol. Invest. 28 4 (2005 (Apr.)) 350-356
19. Massa G., et al. Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. J. Clin. Endocrinol. Metab. 88 9 (2003 (Sep.)) 4168-4174
20. Ranke M.B., et al. Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001. Eur. J. Endocrinol. 147 5 (2002 (Nov.)) 625-633
21. Quigley C.A., et al. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J. Clin. Endocrinol. Metab. 87 5 (2002 (May)) 2033-2041
22. Reiter E.O., et al. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome. J. Clin. Endocrinol. Metab. 86 5 (2001 (May)) 1936-1941
23. Pasquino A.M. Turner syndrome and GH treatment: the state of the art. J. Endocrinol. Invest. 27 11 (2004 (Dec.)) 1072-1075
24. The Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J. Clin. Endocrinol. Metab. 90 6 (2005 (Jun.)) 3360-3366
25. Soriano-Guillen L., et al. Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J. Clin. Endocrinol. Metab. 90 9 (2005 (Sep.)) 5197-5204
26. Carel J.C., et al. Growth hormone therapy for Turner syndrome: evidence for benefit. Horm. Res. 48 Suppl. 5 (1997) 31-34
27. Sas T.C., et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J. Clin. Endocrinol. Metab. 84 12 (1999 (Dec.)) 4607-4612
28. Ranke M.B., et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J. Clin. Endocrinol. Metab. 85 11 (2000 (Nov.)) 4212-4218
29. Davenport M.L., et al. Effect of early growth hormone (GH) treatment in very young girls with Turner syndrome (TS). Lyon, France: 7th Joint ESPE/LWPES Meeting (2005)
30. Sas T.C., et al. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J. Clin. Endocrinol. Metab. 85 2 (2000 (Feb.)) 769-775
31. Cohen P., Clemmons D.R., and Rosenfeld R.G. Does the GH-IGF axis play a role in cancer pathogenesis?. Growth Horm. IGF Res. 10 6 (2000 (Dec.)) 297-305
32. MacGillivray M.H., Baptista J., and Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J. Clin. Endocrinol. Metab. 81 5 (1996 (May)) 1806-1809
33. Jorgensen J.O., et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J. Clin. Endocrinol. Metab. 70 1 (1990 (Jan.)) 207-214
34. Sas T.C., et al. Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. J. Clin. Endocrinol. Metab. 84 12 (1999 (Dec.)) 4622-4628
35. Sas T.C., et al. Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner's syndrome participating in a randomized dose-response study. Pediatr. Res. 50 3 (2001 (Sep.)) 417-422
36. Sas T.C., et al. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clin. Endocrinol. (Oxf.) 52 5 (2000 (May)) 531-536
37. Gravholt C.H., et al. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin. Endocrinol. (Oxf.) 59 1 (2003 (Jul.)) 89-96
38. Bowlby D.A., and Rapaport R. Safety and efficacy of growth hormone therapy in childhood. Pediatr. Endocrinol. Rev. 2 Suppl. 1 (2004 (Nov.)) 68-77
39. Van Pareren Y.K., et al. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 87 12 (2002 (Dec.)) 5442-5448
40. Gravholt C.H., et al. Morbidity in Turner syndrome. J. Clin. Epidemiol. 51 2 (1998 (Feb.)) 147-158
41. Ross J.L., et al. Lipid abnormalities in Turner syndrome. J. Pediatr. 126 2 (1995) 242-245
42. Gravholt C.H., et al. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care 21 7 (1998 (Jul.)) 1062-1070
43. Sas T.C., et al. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. J. Pediatr. 135 4 (1999 (Oct.)) 470-476
44. Donaldson M.D. Growth hormone therapy in Turner syndrome-current uncertainties and future strategies. Horm. Res. 48 Suppl. 5 (1997) 35-44
45. Haeusler G., et al. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr. 85 12 (1996) 1408-1414
46. Nilsson K.O., et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J. Clin. Endocrinol. Metab. 81 2 (1996) 635-640
47. Stahnke N., et al. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J. Pediatr. Endocrinol. Metab. 15 2 (2002 (Feb.)) 129-138
48. Sybert V.P. Adult height in Turner syndrome with and without androgen therapy. J. Pediatr. 104 (1984) 365-369
49. Rosenfield R.L., and Lucky A.W. Oxandrolone therapy for children with Turner syndrome. J. Pediatr. 91 5 (1977 (Nov.)) 854-856
50. Ranke M.B., et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur. J. Pediatr. 141 2 (1983) 81-88
51. Park P., and Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm. Res. 62 Suppl. 1 (2004) 59-65
52. Das U., et al. IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance. Eur. J. Endocrinol. 149 3 (2003 (Sep.)) 179-185
53. Pozo J., et al. The IGF system in childhood: physiology and clinical implications. J. Endocrinol. Invest. 28 5 Suppl. (2005) 38-42
54. Ranke M.B., et al. Predicting the response to recombinant human growth hormone in Turner syndrome: KIGS models. KIGS International Board. Kabi International Growth Study. Acta Paediatr., Suppl. 88 433 (1999 (Dec.)) 122-125
55. Rosenfeld R.G., et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome [see comments]. J. Pediatr. 121 1 (1992) 49-55
56. Rosenfield R.L., et al. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J. Clin. Endocrinol. Metab. 90 12 (2005 (Dec. 1)) 6424-6430
57. Davenport M.L. Evidence for early initiation of growth hormone and transdermal estradiol therapies in girls with Turner syndrome. Growth Horm. IGF Res. 27 (2006 (May))
58. Bannink E.M., et al. Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J. Pediatr. 148 1 (2006 (Jan.)) 95-101
59. Carel J.C., et al. Quality of life determinants in young women with turner's syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J. Clin. Endocrinol. Metab. 90 4 (2005 (Apr.)) 1992-1997